Clicky

Vicore Pharma Holding AB (publ)(VICO)

Description: Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.


Keywords: Pharmaceutical Products Organ Systems Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Interstitial Lung Disease Systemic Sclerosis Interstitial Lung Diseases

Home Page: www.vicorepharma.com

Kronhusgatan 11
Gothenburg, 411 05
Sweden
Phone: 46 3 17 88 05 60


Officers

Name Title
Dr. Carl-Johan Dalsgaard M.D., Ph.D. Chief Exec. Officer
Mr. Hans Jeppsson Ph.D. Chief Financial Officer
Dr. Johan Raud Ph.D. Chief Scientific Officer
Ms. Nina Carlen Chief Admin. Officer
Ms. Johanna Grans Ph.D. Head of Preclinical Devel.
Dr. Kicki Johansson Chief Clinical Devel. Officer
Dr. Rohit Batta Chief Medical Officer
Ms. Elin Rosendahl VP Clinical Devel.
Ms. Jessica Shull Head of Digital Therapeutics
Ms. Asa Magnusson Chief Commercial Officer

Exchange: ST

Country: SE

Currency: Swedish krone (kr)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 8.6737
Price-to-Sales TTM: 0
IPO Date:
Fiscal Year End: December
Full Time Employees: 23
Back to stocks